메뉴 건너뛰기




Volumn 13, Issue 4, 2012, Pages

Genetic heterogeneity and cancer drug resistance

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; IMATINIB;

EID: 84859113048     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70335-7     Document Type: Note
Times cited : (378)

References (84)
  • 1
    • 79953271634 scopus 로고    scopus 로고
    • The evolving war on cancer
    • Haber DA, Gray NS, Baselga J The evolving war on cancer. Cell 2011, 145:19-24.
    • (2011) Cell , vol.145 , pp. 19-24
    • Haber, D.A.1    Gray, N.S.2    Baselga, J.3
  • 2
    • 79957501125 scopus 로고    scopus 로고
    • Human cancers express mutator phenotypes: origin, consequences and targeting
    • Loeb LA Human cancers express mutator phenotypes: origin, consequences and targeting. Nat Rev Cancer 2011, 11:450-457.
    • (2011) Nat Rev Cancer , vol.11 , pp. 450-457
    • Loeb, L.A.1
  • 3
    • 57149118627 scopus 로고    scopus 로고
    • Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia
    • Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008, 322:1377-1380.
    • (2008) Science , vol.322 , pp. 1377-1380
    • Mullighan, C.G.1    Phillips, L.A.2    Su, X.3
  • 4
    • 77951139631 scopus 로고    scopus 로고
    • Genome remodelling in a basal-like breast cancer metastasis and xenograft
    • Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010, 464:999-1005.
    • (2010) Nature , vol.464 , pp. 999-1005
    • Ding, L.1    Ellis, M.J.2    Li, S.3
  • 5
    • 70349969478 scopus 로고    scopus 로고
    • Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution
    • Shah SP, Morin RD, Khattra J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009, 461:809-813.
    • (2009) Nature , vol.461 , pp. 809-813
    • Shah, S.P.1    Morin, R.D.2    Khattra, J.3
  • 6
    • 78751644099 scopus 로고    scopus 로고
    • Genetic variegation of clonal architecture and propagating cells in leukaemia
    • Anderson K, Lutz C, van Delft FW, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011, 469:356-361.
    • (2011) Nature , vol.469 , pp. 356-361
    • Anderson, K.1    Lutz, C.2    van Delft, F.W.3
  • 7
    • 77949809850 scopus 로고    scopus 로고
    • Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas
    • Geyer FC, Weigelt B, Natrajan R, et al. Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol 2010, 220:562-573.
    • (2010) J Pathol , vol.220 , pp. 562-573
    • Geyer, F.C.1    Weigelt, B.2    Natrajan, R.3
  • 9
    • 12944329959 scopus 로고    scopus 로고
    • Chromosomal breakage-fusion-bridge events cause genetic intratumor heterogeneity
    • Gisselsson D, Pettersson L, Hoglund M, et al. Chromosomal breakage-fusion-bridge events cause genetic intratumor heterogeneity. Proc Natl Acad Sci USA 2000, 97:5357-5362.
    • (2000) Proc Natl Acad Sci USA , vol.97 , pp. 5357-5362
    • Gisselsson, D.1    Pettersson, L.2    Hoglund, M.3
  • 10
    • 78049380554 scopus 로고    scopus 로고
    • The patterns and dynamics of genomic instability in metastatic pancreatic cancer
    • Campbell PJ, Yachida S, Mudie LJ, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010, 467:1109-1113.
    • (2010) Nature , vol.467 , pp. 1109-1113
    • Campbell, P.J.1    Yachida, S.2    Mudie, L.J.3
  • 11
    • 78049398107 scopus 로고    scopus 로고
    • Distant metastasis occurs late during the genetic evolution of pancreatic cancer
    • Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010, 467:1114-1117.
    • (2010) Nature , vol.467 , pp. 1114-1117
    • Yachida, S.1    Jones, S.2    Bozic, I.3
  • 12
    • 73649102105 scopus 로고    scopus 로고
    • Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
    • Turke AB, Zejnullahu K, Wu YL, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17:77-88.
    • (2010) Cancer Cell , vol.17 , pp. 77-88
    • Turke, A.B.1    Zejnullahu, K.2    Wu, Y.L.3
  • 13
    • 79953118839 scopus 로고    scopus 로고
    • Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
    • Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3:75ra26.
    • (2011) Sci Transl Med , vol.3
    • Sequist, L.V.1    Waltman, B.A.2    Dias-Santagata, D.3
  • 14
    • 56749098278 scopus 로고    scopus 로고
    • Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor
    • Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008, 26:5352-5359.
    • (2008) J Clin Oncol , vol.26 , pp. 5352-5359
    • Heinrich, M.C.1    Maki, R.G.2    Corless, C.L.3
  • 15
    • 0001686739 scopus 로고    scopus 로고
    • Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
    • Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2:117-125.
    • (2002) Cancer Cell , vol.2 , pp. 117-125
    • Shah, N.P.1    Nicoll, J.M.2    Nagar, B.3
  • 16
    • 75549083303 scopus 로고    scopus 로고
    • Tumor heterogeneity: causes and consequences
    • Marusyk A, Polyak K Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 2010, 1805:105-117.
    • (2010) Biochim Biophys Acta , vol.1805 , pp. 105-117
    • Marusyk, A.1    Polyak, K.2
  • 17
    • 77958014613 scopus 로고    scopus 로고
    • How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
    • Gerlinger M, Swanton C How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer 2010, 103:1139-1143.
    • (2010) Br J Cancer , vol.103 , pp. 1139-1143
    • Gerlinger, M.1    Swanton, C.2
  • 18
    • 51349126920 scopus 로고    scopus 로고
    • Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing
    • Campbell PJ, Pleasance ED, Stephens PJ, et al. Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci USA 2008, 105:13081-13086.
    • (2008) Proc Natl Acad Sci USA , vol.105 , pp. 13081-13086
    • Campbell, P.J.1    Pleasance, E.D.2    Stephens, P.J.3
  • 19
    • 78751661556 scopus 로고    scopus 로고
    • Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells
    • Notta F, Mullighan CG, Wang JC, et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011, 469:362-367.
    • (2011) Nature , vol.469 , pp. 362-367
    • Notta, F.1    Mullighan, C.G.2    Wang, J.C.3
  • 20
    • 33947101019 scopus 로고    scopus 로고
    • Patterns of somatic mutation in human cancer genomes
    • Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
    • (2007) Nature , vol.446 , pp. 153-158
    • Greenman, C.1    Stephens, P.2    Smith, R.3
  • 21
    • 74449085934 scopus 로고    scopus 로고
    • A small-cell lung cancer genome with complex signatures of tobacco exposure
    • Pleasance ED, Stephens PJ, O'Meara S, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010, 463:184-190.
    • (2010) Nature , vol.463 , pp. 184-190
    • Pleasance, E.D.1    Stephens, P.J.2    O'Meara, S.3
  • 22
    • 77249123407 scopus 로고    scopus 로고
    • Signatures of mutation and selection in the cancer genome
    • Bignell GR, Greenman CD, Davies H, et al. Signatures of mutation and selection in the cancer genome. Nature 2010, 463:893-898.
    • (2010) Nature , vol.463 , pp. 893-898
    • Bignell, G.R.1    Greenman, C.D.2    Davies, H.3
  • 24
    • 74449093973 scopus 로고    scopus 로고
    • A comprehensive catalogue of somatic mutations from a human cancer genome
    • Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010, 463:191-196.
    • (2010) Nature , vol.463 , pp. 191-196
    • Pleasance, E.D.1    Cheetham, R.K.2    Stephens, P.J.3
  • 25
    • 79952264848 scopus 로고    scopus 로고
    • A non-genetic route to aneuploidy in human cancers
    • Krajcovic M, Johnson NB, Sun Q, et al. A non-genetic route to aneuploidy in human cancers. Nat Cell Biol 2011, 13:324-330.
    • (2011) Nat Cell Biol , vol.13 , pp. 324-330
    • Krajcovic, M.1    Johnson, N.B.2    Sun, Q.3
  • 26
    • 80051871652 scopus 로고    scopus 로고
    • Aneuploidy drives genomic instability in yeast
    • Sheltzer JM, Blank HM, Pfau SJ, et al. Aneuploidy drives genomic instability in yeast. Science 2011, 333:1026-1030.
    • (2011) Science , vol.333 , pp. 1026-1030
    • Sheltzer, J.M.1    Blank, H.M.2    Pfau, S.J.3
  • 27
    • 80051874823 scopus 로고    scopus 로고
    • Mutational inactivation of STAG2 causes aneuploidy in human cancer
    • Solomon DA, Kim T, Diaz-Martinez LA, et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 2011, 333:1039-1043.
    • (2011) Science , vol.333 , pp. 1039-1043
    • Solomon, D.A.1    Kim, T.2    Diaz-Martinez, L.A.3
  • 28
    • 17244367849 scopus 로고    scopus 로고
    • DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
    • Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
    • (2005) Nature , vol.434 , pp. 864-870
    • Bartkova, J.1    Horejsi, Z.2    Koed, K.3
  • 29
    • 33845235459 scopus 로고    scopus 로고
    • Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
    • Bartkova J, Rezaei N, Liontos M, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444:633-637.
    • (2006) Nature , vol.444 , pp. 633-637
    • Bartkova, J.1    Rezaei, N.2    Liontos, M.3
  • 30
    • 78650959663 scopus 로고    scopus 로고
    • Massive genomic rearrangement acquired in a single catastrophic event during cancer development
    • Stephens PJ, Greenman CD, Fu B, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011, 144:27-40.
    • (2011) Cell , vol.144 , pp. 27-40
    • Stephens, P.J.1    Greenman, C.D.2    Fu, B.3
  • 31
    • 77953658106 scopus 로고    scopus 로고
    • Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2
    • Martin SA, McCarthy A, Barber LJ, et al. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol Med 2009, 1:323-337.
    • (2009) EMBO Mol Med , vol.1 , pp. 323-337
    • Martin, S.A.1    McCarthy, A.2    Barber, L.J.3
  • 32
    • 79953283356 scopus 로고    scopus 로고
    • Genetic interactions in cancer progression and treatment
    • Ashworth A, Lord CJ, Reis-Filho JS Genetic interactions in cancer progression and treatment. Cell 2011, 145:30-38.
    • (2011) Cell , vol.145 , pp. 30-38
    • Ashworth, A.1    Lord, C.J.2    Reis-Filho, J.S.3
  • 33
    • 0036682481 scopus 로고    scopus 로고
    • Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment
    • Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002, 100:1014-1018.
    • (2002) Blood , vol.100 , pp. 1014-1018
    • Roche-Lestienne, C.1    Soenen-Cornu, V.2    Grardel-Duflos, N.3
  • 34
    • 59749086693 scopus 로고    scopus 로고
    • T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense
    • Negri T, Pavan GM, Virdis E, et al. T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense. J Natl Cancer Inst 2009, 101:194-204.
    • (2009) J Natl Cancer Inst , vol.101 , pp. 194-204
    • Negri, T.1    Pavan, G.M.2    Virdis, E.3
  • 35
    • 72949119310 scopus 로고    scopus 로고
    • Complex landscapes of somatic rearrangement in human breast cancer genomes
    • Stephens PJ, McBride DJ, Lin ML, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009, 462:1005-1010.
    • (2009) Nature , vol.462 , pp. 1005-1010
    • Stephens, P.J.1    McBride, D.J.2    Lin, M.L.3
  • 36
    • 67650434696 scopus 로고    scopus 로고
    • Lessons from an aggressive cancer: evolutionary dynamics in esophageal carcinoma
    • Klein CA, Stoecklein NH Lessons from an aggressive cancer: evolutionary dynamics in esophageal carcinoma. Cancer Res 2009, 69:5285-5288.
    • (2009) Cancer Res , vol.69 , pp. 5285-5288
    • Klein, C.A.1    Stoecklein, N.H.2
  • 37
    • 33748286796 scopus 로고    scopus 로고
    • A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers
    • Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006, 38:1043-1048.
    • (2006) Nat Genet , vol.38 , pp. 1043-1048
    • Carter, S.L.1    Eklund, A.C.2    Kohane, I.S.3    Harris, L.N.4    Szallasi, Z.5
  • 38
    • 42949150219 scopus 로고    scopus 로고
    • Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer
    • Stoecklein NH, Hosch SB, Bezler M, et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 2008, 13:441-453.
    • (2008) Cancer Cell , vol.13 , pp. 441-453
    • Stoecklein, N.H.1    Hosch, S.B.2    Bezler, M.3
  • 39
    • 79956160582 scopus 로고    scopus 로고
    • Paradoxical relationship between chromosomal instability and survival outcome in cancer
    • Birkbak NJ, Eklund AC, Li Q, et al. Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res 2011, 71:3447-3452.
    • (2011) Cancer Res , vol.71 , pp. 3447-3452
    • Birkbak, N.J.1    Eklund, A.C.2    Li, Q.3
  • 40
    • 0001641514 scopus 로고
    • Mutations of bacteria from virus sensitivity to virus resistance
    • Luria SE, Delbruck M Mutations of bacteria from virus sensitivity to virus resistance. Genetics 1943, 28:491-511.
    • (1943) Genetics , vol.28 , pp. 491-511
    • Luria, S.E.1    Delbruck, M.2
  • 41
    • 77954740501 scopus 로고    scopus 로고
    • Metastatic behavior of breast cancer subtypes
    • Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010, 28:3271-3277.
    • (2010) J Clin Oncol , vol.28 , pp. 3271-3277
    • Kennecke, H.1    Yerushalmi, R.2    Woods, R.3
  • 43
    • 69249087671 scopus 로고    scopus 로고
    • Environment-mediated drug resistance: a major contributor to minimal residual disease
    • Meads MB, Gatenby RA, Dalton WS Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009, 9:665-674.
    • (2009) Nat Rev Cancer , vol.9 , pp. 665-674
    • Meads, M.B.1    Gatenby, R.A.2    Dalton, W.S.3
  • 45
    • 77953066865 scopus 로고    scopus 로고
    • The microenvironment determines the breast cancer cells' phenotype: organization of MCF7 cells in 3D cultures
    • Krause S, Maffini MV, Soto AM, Sonnenschein C The microenvironment determines the breast cancer cells' phenotype: organization of MCF7 cells in 3D cultures. BMC Cancer 2010, 10:263.
    • (2010) BMC Cancer , vol.10 , pp. 263
    • Krause, S.1    Maffini, M.V.2    Soto, A.M.3    Sonnenschein, C.4
  • 47
    • 33750313208 scopus 로고    scopus 로고
    • Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells
    • Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006, 66:9339-9344.
    • (2006) Cancer Res , vol.66 , pp. 9339-9344
    • Clarke, M.F.1    Dick, J.E.2    Dirks, P.B.3
  • 48
    • 84855332744 scopus 로고    scopus 로고
    • Breast cancer stem cells: beyond semantics
    • Badve S, Nakshatri H Breast cancer stem cells: beyond semantics. Lancet Oncol 2012, 13:e43-e48.
    • (2012) Lancet Oncol , vol.13
    • Badve, S.1    Nakshatri, H.2
  • 50
    • 79956351015 scopus 로고    scopus 로고
    • Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state
    • Chaffer CL, Brueckmann I, Scheel C, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 2011, 108:7950-7955.
    • (2011) Proc Natl Acad Sci USA , vol.108 , pp. 7950-7955
    • Chaffer, C.L.1    Brueckmann, I.2    Scheel, C.3
  • 51
    • 80051967505 scopus 로고    scopus 로고
    • Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells
    • Gupta PB, Fillmore CM, Jiang G, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011, 146:633-644.
    • (2011) Cell , vol.146 , pp. 633-644
    • Gupta, P.B.1    Fillmore, C.M.2    Jiang, G.3
  • 52
    • 32944457518 scopus 로고    scopus 로고
    • MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
    • O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.
    • (2006) Cancer Res , vol.66 , pp. 1500-1508
    • O'Reilly, K.E.1    Rojo, F.2    She, Q.B.3
  • 53
    • 51349164790 scopus 로고    scopus 로고
    • Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
    • Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008, 118:3065-3074.
    • (2008) J Clin Invest , vol.118 , pp. 3065-3074
    • Carracedo, A.1    Ma, L.2    Teruya-Feldstein, J.3
  • 54
    • 77956579297 scopus 로고    scopus 로고
    • A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors
    • abstr 3008.
    • Di Cosimo S, Bendell JC, Cervantes-Ruiperez A, et al. A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol 2010, 28(suppl). abstr 3008.
    • (2010) Proc Am Soc Clin Oncol , vol.28 , Issue.SUPPL.
    • Di Cosimo, S.1    Bendell, J.C.2    Cervantes-Ruiperez, A.3
  • 55
    • 77950809059 scopus 로고    scopus 로고
    • A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
    • Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
    • (2010) Cell , vol.141 , pp. 69-80
    • Sharma, S.V.1    Lee, D.Y.2    Li, B.3
  • 56
    • 54949085398 scopus 로고    scopus 로고
    • K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    • Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
    • (2008) N Engl J Med , vol.359 , pp. 1757-1765
    • Karapetis, C.S.1    Khambata-Ford, S.2    Jonker, D.J.3
  • 57
    • 24944497744 scopus 로고    scopus 로고
    • Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
    • Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23:5900-5909.
    • (2005) J Clin Oncol , vol.23 , pp. 5900-5909
    • Eberhard, D.A.1    Johnson, B.E.2    Amler, L.C.3
  • 58
    • 50249092801 scopus 로고    scopus 로고
    • Heterogeneity of kinase inhibitor resistance mechanisms in GIST
    • Liegl B, Kepten I, Le C, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 2008, 216:64-74.
    • (2008) J Pathol , vol.216 , pp. 64-74
    • Liegl, B.1    Kepten, I.2    Le, C.3
  • 59
    • 78349265779 scopus 로고    scopus 로고
    • Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer
    • Suda K, Murakami I, Katayama T, et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 2010, 16:5489-5498.
    • (2010) Clin Cancer Res , vol.16 , pp. 5489-5498
    • Suda, K.1    Murakami, I.2    Katayama, T.3
  • 60
    • 78649436372 scopus 로고    scopus 로고
    • BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation
    • Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 2010, 3:ra84.
    • (2010) Sci Signal , vol.3
    • Corcoran, R.B.1    Dias-Santagata, D.2    Bergethon, K.3    Iafrate, A.J.4    Settleman, J.5    Engelman, J.A.6
  • 61
    • 80051625929 scopus 로고    scopus 로고
    • Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling
    • Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011, 29:3085-3096.
    • (2011) J Clin Oncol , vol.29 , pp. 3085-3096
    • Wagle, N.1    Emery, C.2    Berger, M.F.3
  • 62
    • 17244373777 scopus 로고    scopus 로고
    • Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
    • Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
    • (2005) Nature , vol.434 , pp. 917-921
    • Farmer, H.1    McCabe, N.2    Lord, C.J.3
  • 63
    • 39849097680 scopus 로고    scopus 로고
    • Resistance to therapy caused by intragenic deletion in BRCA2
    • Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008, 451:1111-1115.
    • (2008) Nature , vol.451 , pp. 1111-1115
    • Edwards, S.L.1    Brough, R.2    Lord, C.J.3
  • 64
    • 80051642095 scopus 로고    scopus 로고
    • Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas
    • Norquist B, Wurz KA, Pennil CC, et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 2011, 29:3008-3015.
    • (2011) J Clin Oncol , vol.29 , pp. 3008-3015
    • Norquist, B.1    Wurz, K.A.2    Pennil, C.C.3
  • 65
    • 77953930730 scopus 로고    scopus 로고
    • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    • Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
    • (2010) N Engl J Med , vol.362 , pp. 2380-2388
    • Maemondo, M.1    Inoue, A.2    Kobayashi, K.3
  • 66
    • 33845444046 scopus 로고    scopus 로고
    • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
    • Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
    • (2006) N Engl J Med , vol.355 , pp. 2408-2417
    • Druker, B.J.1    Guilhot, F.2    O'Brien, S.G.3
  • 67
  • 68
    • 0035810142 scopus 로고    scopus 로고
    • Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
    • Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038-1042.
    • (2001) N Engl J Med , vol.344 , pp. 1038-1042
    • Druker, B.J.1    Sawyers, C.L.2    Kantarjian, H.3
  • 69
    • 79960435101 scopus 로고    scopus 로고
    • Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer
    • Molinari F, Felicioni L, Buscarino M, et al. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res 2011, 17:4901-4914.
    • (2011) Clin Cancer Res , vol.17 , pp. 4901-4914
    • Molinari, F.1    Felicioni, L.2    Buscarino, M.3
  • 70
    • 80051965827 scopus 로고    scopus 로고
    • Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer
    • Zhou Q, Zhang XC, Chen ZH, et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011, 29:3316-3321.
    • (2011) J Clin Oncol , vol.29 , pp. 3316-3321
    • Zhou, Q.1    Zhang, X.C.2    Chen, Z.H.3
  • 71
    • 70349254450 scopus 로고    scopus 로고
    • Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
    • Soverini S, Gnani A, Colarossi S, et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 2009, 114:2168-2171.
    • (2009) Blood , vol.114 , pp. 2168-2171
    • Soverini, S.1    Gnani, A.2    Colarossi, S.3
  • 72
    • 66149098947 scopus 로고    scopus 로고
    • Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer
    • Attard G, Swennenhuis JF, Olmos D, et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009, 69:2912-2918.
    • (2009) Cancer Res , vol.69 , pp. 2912-2918
    • Attard, G.1    Swennenhuis, J.F.2    Olmos, D.3
  • 73
    • 67349257845 scopus 로고    scopus 로고
    • Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer
    • Liu W, Laitinen S, Khan S, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009, 15:559-565.
    • (2009) Nat Med , vol.15 , pp. 559-565
    • Liu, W.1    Laitinen, S.2    Khan, S.3
  • 74
    • 24744443720 scopus 로고    scopus 로고
    • High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy
    • Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005, 106:2128-2137.
    • (2005) Blood , vol.106 , pp. 2128-2137
    • Willis, S.G.1    Lange, T.2    Demehri, S.3
  • 75
    • 77955911497 scopus 로고    scopus 로고
    • Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma
    • Inda MM, Bonavia R, Mukasa A, et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 2010, 24:1731-1745.
    • (2010) Genes Dev , vol.24 , pp. 1731-1745
    • Inda, M.M.1    Bonavia, R.2    Mukasa, A.3
  • 76
    • 26844503270 scopus 로고    scopus 로고
    • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    • Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
    • (2005) N Engl J Med , vol.353 , pp. 1659-1672
    • Piccart-Gebhart, M.J.1    Procter, M.2    Leyland-Jones, B.3
  • 77
    • 26844536978 scopus 로고    scopus 로고
    • Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    • Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
    • (2005) N Engl J Med , vol.353 , pp. 1673-1684
    • Romond, E.H.1    Perez, E.A.2    Bryant, J.3
  • 79
    • 52949116364 scopus 로고    scopus 로고
    • The role of cytoreductive/debulking surgery in ovarian cancer
    • quiz 11.
    • Wakabayashi MT, Lin PS, Hakim AA The role of cytoreductive/debulking surgery in ovarian cancer. J Natl Compr Canc Netw 2008, 6:803-810. quiz 11.
    • (2008) J Natl Compr Canc Netw , vol.6 , pp. 803-810
    • Wakabayashi, M.T.1    Lin, P.S.2    Hakim, A.A.3
  • 80
    • 78650387260 scopus 로고    scopus 로고
    • CyberKnife stereotactic radiosurgery for intracranial neoplasms, with a focus on malignant tumors
    • Bucholz RD, Laycock KA, Cuff LE CyberKnife stereotactic radiosurgery for intracranial neoplasms, with a focus on malignant tumors. Technol Cancer Res Treat 2010, 9:541-550.
    • (2010) Technol Cancer Res Treat , vol.9 , pp. 541-550
    • Bucholz, R.D.1    Laycock, K.A.2    Cuff, L.E.3
  • 81
    • 33646256145 scopus 로고    scopus 로고
    • A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy
    • Hunter C, Smith R, Cahill DP, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 2006, 66:3987-3991.
    • (2006) Cancer Res , vol.66 , pp. 3987-3991
    • Hunter, C.1    Smith, R.2    Cahill, D.P.3
  • 82
    • 77953725855 scopus 로고    scopus 로고
    • Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
    • Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362:2260-2270.
    • (2010) N Engl J Med , vol.362 , pp. 2260-2270
    • Kantarjian, H.1    Shah, N.P.2    Hochhaus, A.3
  • 83
    • 77953691179 scopus 로고    scopus 로고
    • Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
    • Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362:2251-2259.
    • (2010) N Engl J Med , vol.362 , pp. 2251-2259
    • Saglio, G.1    Kim, D.W.2    Issaragrisil, S.3
  • 84
    • 0037206022 scopus 로고    scopus 로고
    • Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer
    • Klein CA, Blankenstein TJ, Schmidt-Kittler O, et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002, 360:683-689.
    • (2002) Lancet , vol.360 , pp. 683-689
    • Klein, C.A.1    Blankenstein, T.J.2    Schmidt-Kittler, O.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.